S415 Increasing Prevalence of Eosinophilic Esophagitis in the United States from 2015 to 2018
Siddhesh Kamat(Regeneron (United States)), Mirna Chehade(Icahn School of Medicine at Mount Sinai), Urvi Mujumdar(Memorial Sloan Kettering Cancer Center), Eilish McCann(Regeneron (United States)), Chien-Chia Chuang, Jessica J. Jalbert(Regeneron (United States)), Degang Wang(Regeneron (United States))
Cited by 3
Related Papers
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
|New England Journal of Medicine|2022|452
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
|New England Journal of Medicine|2024|107
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2023|100
Feeding difficulties in children with non–IgE-mediated food allergic gastrointestinal disorders
|Annals of Allergy Asthma & Immunology|2019|55
Open-label, add-on trial of cetirizine for neuromyelitis optica
|Neurology Neuroimmunology & Neuroinflammation|2018|26